Hepatitis B Virus

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients

Published in Hepatitis Weekly, January 30th, 2006

According to a study from Italy, adefovir dipivoxil (ADV) rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.

"Progression of hepatitis B in patients with lamivudine-resistant strains is slowed down by ADV. Whether the time point of ADV administration (genotypic vs. phenotypic resistance) influences the outcome of therapy is unknown."

"We compared the outcome of ADV therapy in hepatitis Be antigen (HBeAg)-negative chronic hepatitis B patients with genotypic and phenotypic resistance to lamivudine," wrote P. Lampertico and colleagues, University of Milan.

"Ten milligrams of ADV...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-01-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry